Carotid artery stenting outcomes: Do they correlate with antiplatelet response assays?

Journal of NeuroInterventional Surgery

Volumn 6, Issue 5, 2014, Pages 373-378

  Sorkin, Grant C ^a,b   Dumont, Travis M ^a,b   Wach, Michael M ^a,b   Eller, Jorge L ^a,b   Mokin, Maxim ^a,b   Natarajan, Sabareesh K ^a,b   Baxter, Melissa S ^c   Snyder, Kenneth V ^a,b,c   Levy, Elad I ^a,b,c   Hopkins, L Nelson ^a,b,c,d   Siddiqui, Adnan H ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Gates Vascular Institute   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d JACOBS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; AGED; ANTIPLATELET RESPONSE ASSAY; ARTICLE; ASSAY; BRAIN HEMORRHAGE; CAROTID ARTERY STENTING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CORRELATIONAL STUDY; DRUG MONITORING; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN ISCHEMIA; CAROTID STENOSIS; CEREBRAL REVASCULARIZATION; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PREVALENCE; PROCEDURES; REGISTER; STATISTICS AND NUMERICAL DATA; STENT; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; CAROTID STENOSIS; CEREBRAL REVASCULARIZATION; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; RETROSPECTIVE STUDIES; STENTS; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84901916978     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2013-010771     Document Type: Article

References (29)

1. Fiorella D, Thiabolt L, Albuquerque FC, et al. Antiplatelet therapy in neuroendovascular therapeutics. Neurosurg Clin N Am 2005;16:517-40, vi. (Pubitemid 41766379)
2. Lee DH, Arat A, Morsi H, et al. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389-94.
3. Lopes D, Mangubat E, Keigher K, et al. Intracranial stents in SAH cases. Endovasc Today 2010:62-4.
4. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-5. (Pubitemid 351287881)
5. Ryu DS, Hong CK, Sim YS, et al. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 2010;48:319-24.
6. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62.
7. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-5. (Pubitemid 44522148)
8. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50. (Pubitemid 44648629)
9. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132-7.
10. Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial substudy. J Am Coll Cardiol 2010;56:1447-55.
11. Campo G, Valgimigli M, Frangione A, et al. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel). J Am Coll Cardiol 2010;55:255-6.
12. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) study. J Am Coll Cardiol 2012;59:2159-64.
13. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22.
14. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84. (Pubitemid 44918092)
15. Malinin A, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301. (Pubitemid 38757056)
16. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
17. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17. (Pubitemid 44343544)
18. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53. (Pubitemid 350182388)
19. Bonello L, Tantry US, Marcucci R, et al. Working Group on High-on-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
20. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42.
21. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-33.
22. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. (Pubitemid 351844676)
23. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
24. Brott TG, Hobson RW II, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11-23.
25. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. (Pubitemid 35340537)
26. Goh C, Churilov L, Mitchell P, et al. Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. AJNR Am J Neuroradiol 2013;34:721-6.
27. Eli Lilly and Company. Effient (prasugrel) tablets (package insert). Indianapolis IN; 2011 http://pi.lilly.com/us/effient.pdf (accessed 2 Apr 2013).
28. AstraZeneca. Brilinta (ticagrelor) tablets (package insert). Wilmington DE; 2011. http://www1.astrazeneca-us.com/pi/brilinta.pdf (accessed 2 Apr 2013).
29. Genpharm. Ticlopidine hydrochloride tablets (package insert). Toronto, Canada; 2008. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 8668#nlm42230-3 (accessed 2 Apr 2013).